As of March 31, 2025 and December 31, 2024, the company had cash, cash equivalents and marketable securities totaling $159.5 million and $171.4 million, respectively. Research and development expenses for the first quarter 2025 were $2.0 million, compared to $26.0 for the first quarter 2024. The decrease was primarily due to lower clinical development costs.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.